PHPN Stock Chart & Stats
€4.60
-€0.07(-6.19%)
At close: 4:00 PM EST
€4.60
-€0.07(-6.19%)
Day’s Range― - ―
52-Week Range€1.61 - €5.80
Previous CloseN/A
Volume0.00
Average Volume (3M)23.00
Market Cap
€202.45M
Enterprise Value€307.34
Total Cash (Recent Filing)€14.11M
Total Debt (Recent Filing)€135.72M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume0
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.62Price Target Upside109.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Alignment For Phase 3FDA agreement on a single adequate, well‑controlled Phase 3 design and accepted blinded central endoscopy review materially reduces regulatory uncertainty. That durable de‑risking strengthens the path to potential approval, improves partnerability and clarifies long‑term development requirements.
Improving Cash Burn TrendA meaningful reduction in cash burn versus prior year indicates better cost discipline or streamlined operations, extending runway and lowering near‑term financing pressure. Sustained improvement increases ability to fund Phase 3 planning and attract strategic partners over the coming months.
Focused Galectin‑3 PipelineA concentrated scientific focus on galectin‑3 and a lead candidate creates a clear platform advantage: deep expertise, streamlined R&D priorities and multiple therapeutic applications (fibrosis, inflammation, oncology). This structural specialization aids partner interest and efficient resource allocation.
Bears Say
No Commercial RevenueAbsence of operating revenue means the business relies entirely on financing to fund operations and trials. Persistent net losses undermine self‑funding capacity, increase dilution risk from future raises, and leave long‑term viability contingent on successful clinical outcomes or partner deals.
Highly Leveraged Balance SheetDeeply negative equity and substantial debt relative to assets constrain financial flexibility and raise refinancing and covenant risk. High leverage limits the firm's ability to absorb trial delays, increases cost of capital, and can force unfavorable financing terms or accelerated dilution.
Dependence On Partners/financingReliance on external strategic or financial partners to fund Phase 3 and commercialization creates execution risk: partner interest, timing, and deal terms will materially affect program timelines, control and economics, and could delay or alter clinical development plans.
Galectin Therapeutics News
PHPN FAQ
What was Galectin Therapeutics (GALT)’s price range in the past 12 months?
Galectin Therapeutics (GALT) lowest stock price was €1.61 and its highest was €5.80 in the past 12 months.
What is Galectin Therapeutics (GALT)’s market cap?
Galectin Therapeutics (GALT)’s market cap is €202.45M.
When is Galectin Therapeutics (GALT)’s upcoming earnings report date?
Galectin Therapeutics (GALT)’s upcoming earnings report date is Aug 17, 2026 which is in 23 days.
How were Galectin Therapeutics (GALT)’s earnings last quarter?
Galectin Therapeutics (GALT) released its earnings results on May 15, 2026. The company reported -€0.07 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Galectin Therapeutics (GALT) overvalued?
According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued.
Does Galectin Therapeutics (GALT) pay dividends?
Galectin Therapeutics (GALT) does not currently pay dividends.
What is Galectin Therapeutics (GALT)’s EPS estimate?
Galectin Therapeutics (GALT)’s EPS estimate is -0.08.
How many shares outstanding does Galectin Therapeutics (GALT) have?
Galectin Therapeutics (GALT) has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?
Galectin Therapeutics (GALT) reported an EPS of -€0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?
Currently, no hedge funds are holding shares in DE:PHPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.62 (109.02% Upside)
€9.62 (109.02% Upside)
Blogger Sentiment
Bullish
DE:PHPN Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics (GALT)
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
PHPN Stock 12 Month Forecast
Average Price Target
€9.62
▲(109.02% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―